Letters to the Editor Fibromuscular Dysplasia, Antiovulent Drugs, and Ergot Preparations
To the Editor:
Fibromuscular dysplasia of the carotid arteries was not described by the founders of pathology or of neurology, and not recognized clinically until 1965.' Personal experience with 6 female patients, as well as reports in the literature, leads me to suggest that the condition is not rare, and a recent article in STROKE 2 reports 25 patients. The cause for increased recognition of fibromuscular dysplasia, in both carotid and renal vessels, may be the increased use of angiography; but the etiology of fibromuscular dysplasia remains unknown.
Review of 21 articles reporting cases of fibromuscular dysplasia of the carotid vessels confirms the statement by Iosue and Stanley 3 ' * that 80 to 85% of cases are females, and several articles since that of Hartman 5 in 1971 have suggested that antiovulent or estrogen medications can be causally related. Three of 6 patients we have seen had received ergot preparations.
Internists and neurologists are well aware of limb ischemia and vascular occlusion induced by prolonged use of ergot preparations in susceptible individuals. The entity of ergotamine headache 6 has also become increasingly recognized, and it is clear that migrainous individuals who persist in regular use of ergot preparations may have persistent incapacitating headaches with or without symptoms of peripheral ischemia. Ergot can produce significant, but reversible, effects in the carotid arteries. Richter and Banker 7 are among those who have reported patients with so called "carotid ergotism."
The vulnerability of the carotid and renal arteries to fibromuscular dysplasia has been attributed to the relative dependence of these vessels on nutrition from the vaso vasorum originating from the lumen of these muscular arteries, in contrast to other vessels which have a more stable vascular supply. Stanley et al. 4 have further suggested that regions of particular stretch or stress, such as the right renal or both carotid arteries, are particularly vulnerable to episodic ischemia. An additional concept possibly applicable in the explanation of fibromuscular dysplasia is the monoclonal hypothesis 8 which suggests that the proliferating cells of an early arteriosclerotic plaque stem from one mutated cell. Such cells may be stimulated by ischemia, toxins, or stretch; and the effect of estrogen is to enhance such neoplastic proliferation of smooth muscle cells.
It can thus be hypothesized that fibromuscular dysplasia is the result of inappropriate multiplication of cells in certain muscular arteries, and that such proliferation is enhanced by antiovulants. In addition to pregnancy, hormones, hypertension, stretch, and genetic predisposition, the use of ergot preparations may also enhance such vascular changes. Although not emphasized in the literature, a long history of chronic, even throbbing, headaches has been mentioned in many of the case reports on fibromuscular dysplasia. There are experimental approaches on the effect of ergot on the cells of muscular arteries, and there are potential epidemiologic approaches to any linkage between ergot or hormonal therapy and "spontaneous" vascular catastrophies such as fibromuscular dysplasia. Until the etiology of fibromuscular dysplasia becomes clear, reduction in blood pressure, avoidance of estrogen, and elimination of antimigrainous agents all seem suitable approaches in the medical management of such cases.
George W. Paulson, M.D.

Clinical Professor of Neurology Riverside Methodist Hospital and The Ohio State University School of Medicine
Carotid Endarterectomy: Mortality Rate
I have read the article on stroke and mortality in carotid endarterectomy in your September-October issue ("Stroke and Mortality Rate in Carotid Endarterectomy: 228 Consecutive Operations" by J. Donald Easton and David G. Sherman, Vol. 8: 565, 1977) . After reading this and realizing the horrifying impact of the conclusions, my feelings are that this represents a great step backward in their treatment of stroke. It takes a considerable amount of courage to publish such poor numbers for what should be a rather straight-forward procedure: carotid endarterectomy.
The mortality rate should approach the ideal, which has been established by Dr. Jesse Thompson and is referred to by the authors. Thompson has reported a morbidity/mortality rate of 0.2%; his results are probably the best in the world, and he has achieved these by a thorough knowledge of the physiology involved, the operation itself and the management of the patient both during and in the postoperative period.
It might be well for us to review briefly some of the problems involved and point out to the authors and the readers of this column alike why we feel that Drs. Easton and Sherman have contributed something in a negative fashion. Although it would appear superficially that this is a well-prepared manuscript, it has all the appearances of a basket of fruit containing disparate members of a particular genus; i.e., apples, pears and whatnot. It is surprising to me that the editors found this article worthy of publication.
Having made some serious criticisms, it is incumbent upon us now to be constructive.
Starting at no particular place in the communication, the mere statement that there is similarity of results among 11 Board certified neurological and vascular surgeons has no bearing on the matter whatsoever. The statement that these men are Board certified does not attest in any way to their skill or knowledge of the subject; merely that they sat for their Boards and are probably competent to a certain degree in their specialty. It does not otherwise indicate their particular skills in the management of carotid artery disease.
Patient selection is fairly straight-forward and has been delineated by many of the authors referred to in the References. It's important to know whether we're dealing with a patient who has progressive TIAs, stable TIAs and asymptomatic bruit or a patient with a sudden frank stroke. Here it would seem that the symptoms and the timing would be important factors.
Oculoplethysmographic studies will give us an idea of whether there is a stenotic component associated with the TIAs, whether 
